Twenty-seven percent of Americans and Canadians aged 16 to 65 have used cannabis for medical purposes. About half of those users — roughly 13 percent of the total adult population — are using it specifically to manage their mental health: anxiety, depression, or PTSD.
In March 2026, The Lancet Psychiatry published the largest review of medicinal cannabis and mental health ever conducted. It analyzed 54 randomized controlled trials spanning 45 years of data. The conclusion was unambiguous: there is no reliable evidence that cannabis effectively treats anxiety, depression, or PTSD.
"For a long time, people have been using cannabis to cope with mental illness," said Dr. Jack Wilson of the University of Sydney's Matilda Centre, who led the study. "Our findings show that belief in its effectiveness may be outpacing the evidence."
What the Study Actually Found
The Lancet Psychiatry meta-analysis is the most comprehensive examination of medicinal cannabis and mental health ever published. Fifty-four randomized controlled trials — the gold standard of clinical evidence — across 45 years of data. The conditions examined included anxiety disorders, depression, PTSD, psychosis, bipolar disorder, ADHD, Tourette syndrome, and substance use disorders.
The findings for the three conditions driving the largest share of medical cannabis use were consistent: no good evidence of effectiveness. For anxiety, depression, and PTSD — the conditions most commonly cited as reasons for cannabis use in North America, Australia, and Europe — the pooled data from controlled trials did not support cannabis as an effective treatment.
Some conditions showed limited, low-certainty evidence of modest benefit: insomnia and certain symptoms in autism spectrum disorder. But the researchers were careful to note that "low-certainty evidence" is not the same as evidence of effectiveness, and that the studies in these categories were small and methodologically limited.
The Risk That Goes Beyond Not Working
The study's findings don't just challenge whether cannabis helps with anxiety and depression. They raise a harder question: whether it might make things worse.
According to the University of Sydney research team, cannabis use carries documented risks of psychosis, addiction, and dependence — particularly with high-potency products and frequent use. The risk profile varies significantly by product, dosage, and individual factors, but it is real and documented across multiple independent bodies of research.
More concerning from a public health perspective: when people use cannabis to manage anxiety or depression and experience some relief — even temporary — they may delay accessing treatments that have strong clinical evidence behind them. Cognitive behavioral therapy, SSRI medications, and other evidence-based treatments for anxiety and depression have decades of robust trial data. Cannabis, for these conditions, does not.
"These findings call into question the approval of medicinal cannabis for depression, anxiety and PTSD," Wilson said, noting that some US states specifically authorize cannabis for patients with these diagnoses.
Why So Many People Believe It Helps
The gap between the clinical evidence and the personal experience of millions of users is real, and it deserves an honest explanation rather than dismissal.
Cannabis does produce measurable short-term effects on anxiety and mood — particularly through its action on the endocannabinoid system, which plays a role in emotional regulation. The relief many users report is genuine in the moment. What the clinical trial evidence doesn't support is that this short-term relief translates into meaningful, lasting improvement in anxiety disorders, depression, or PTSD when measured against placebo in controlled conditions.
Scientific American's coverage of the study noted that part of the challenge is that cannabis users often report significant personal benefit — but anecdotal experience and placebo effects are specifically what randomized controlled trials are designed to separate from genuine treatment effects. When you do that separation, at scale, across 54 trials and 45 years, the signal disappears.
There is one important nuance: CBD alone, as distinct from cannabis products containing THC, showed some emerging low-certainty evidence of anxiety reduction in the Lancet review and in a concurrent PubMed analysis. This is not the same as saying CBD-containing cannabis products are effective treatments — but it is the direction researchers say the more promising signals are pointing.
What This Means for People Currently Using Cannabis for Mental Health
The study's authors are explicit that these findings should inform both clinicians prescribing cannabis and individuals using it. The specific implication: if you are managing anxiety, depression, or PTSD with cannabis and not also accessing evidence-based treatments, the research suggests you may be investing in something that isn't working while delaying access to something that might.
That is not a judgment about why people use cannabis or what they experience when they do. It is a statement about what the largest body of controlled evidence currently shows — and what it doesn't.
